Clinipace Worldwide Joins American Society of Nephrology’s Kidney Health Initiative

Move is Part of Company’s Expanded Commitment to Nephrology

MORRISVILLE, N.C.–(BUSINESS WIRE)–#clinicalresearch–Clinipace Worldwide, a global digital contract research organization
(dCRO), announced today that it has become a member
of the American Society of Nephrology’s Kidney
Health Initiative
(KHI).

The KHI mission
is to advance scientific understanding of the kidney health and patient
safety implications of new and existing medical products, and to foster
development of therapies for diseases that affect the kidney. The
initiative plans to achieve this by creating a collaborative environment
in which the U.S. Food and Drug Administration and the greater
nephrology community can interact to optimize evaluation of drugs,
devices, biologics, and food products.

“The decision to join the ASN Kidney Health Initiative is an important
element in our expanded commitment to the nephrology field,” said
Clinipace President and CEO Jeff Williams. “We fully support the KHI
goal of improving patient safety and promoting development of new
therapies for all patients with kidney disease, a major public health
issue that affects up to 26 million Americans.”

Clinipace representatives will attend the Fifth Annual KHI Stakeholders
Meeting in Washington, DC, on May 24-25, 2017. This meeting will bring
together the diverse membership of the KHI from the kidney community to
connect members across different fields, share ideas, collect feedback,
and collaborate on new and proposed projects.

Also in this therapeutic area, in April 2017, Clinipace appointed
eminent nephrologist Eric B. Grossman, MD, as Vice President and Medical
Director. With over 30 years of industry and clinical experience, Dr.
Grossman brings almost two decades of experience designing and
conducting clinical studies in therapeutic areas including nephrology,
cardiovascular, diabetes, urology, women’s health and oncology. Dr.
Grossman previously held positions with Bexon Clinical Consulting, Reata
Pharmaceuticals, Keryx Biopharmaceuticals, the New York Organ Donor
Network and Pfizer. Dr. Grossman received an MD from the University of
Chicago Pritzker School of Medicine. He completed his residency at the
Tufts-New England Medical Center and his nephrology fellowship at
Harvard Medical School’s Brigham and Women’s Hospital in Boston.

About Clinipace Worldwide

Clinipace Worldwide, a digital contract research organization (dCRO),
pioneered an innovative, technology-amplified CRO service model to serve
the unique needs of venture-backed, mid-tier and strategic
pharmaceutical, biotechnology and medical device firms.

Powered by Clinipace’s proprietary TEMPO™ eClinical platform and a team
of experts with extensive knowledge in therapeutic areas such as
oncology, cardiovascular, and metabolic diseases, gastroenterology,
infectious diseases, nephrology, immunology and vaccines, the company
assists life science firms in successfully executing regulatory
strategies, clinical development and post-approval research programs. To
learn more, visit www.Clinipace.com.

Contacts

Clinipace Worldwide
Sandra Parrish Woodlief, 919-797-9480
swoodlief@clinipace.com